Pfizer and biontech initiate study to evaluate omicron-based covid-19 vaccine in adults 18 to 55 years of age

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an omicron-based vaccine candidate in healthy adults 18 through 55 years of age. the study will have three cohorts examining different regimens of the current pfizer-biontech covid-19 vaccine or an omicron-based vaccine. the study will draw upon some participants from the companies' phase
BNTX Ratings Summary
BNTX Quant Ranking